A Stearyl‐Peptide Based Versatile Strategy to Design Enzyme‐Responsive Liposomes for Targeted Drug Delivery

Liposomes are a prominent class of drug delivery nanoparticles. For currently approved liposomal therapeutics, drug is released predominantly via diffusion which has spatio-temporal kinetic and bioavailability challenges, especially in a dynamic environment. Next-generation liposome designs focus on stimuli-triggered enhancement of drug release. One exciting approach here is liposomes that can be site-specifically destabilized by disease-associated enzymes. Feasibility of this has been demonstrated with certain phospholipases or metalloproteases, but a versatile strategy for designing liposomes triggerable by any disease-specific enzyme remains lacking. We report a unique liposome design using enzyme-cleavable stearyl-peptide conjugates. Stearylamine has been explored for cationic liposomes in gene delivery, but the cationic charge poses significant cytotoxicity. We demonstrate that conjugating enzyme-cleavable peptides to stearylamine and assembly of stearyl-peptide conjugates within liposomes mitigates the cationic charge and significantly enhances biosafety. Surface-decorating such liposomes with target-specific ligands enables their active target-anchorage under flow. Exposure of target-anchored liposomes to disease-relevant enzymes renders stearyl-peptide cleavage and liposome destablization, enhancing drug release. We demonstrate the design versatility utilizing microfluidic models of three different vascular pathologies (hyperfibrinolysis, thrombosis and thromboinflammation) and delivering three corresponding drugs (tranexamic acid, tissue plasminogen activator and deoxyribonulease) triggered by three different enzymes (plasmin, thrombin and neutrophil elastase), respectively.

Authors

Institutions

Publication Details

Journal
Advanced Healthcare Materials
Published
2026-11-17
DOI
https://doi.org/10.1002/adhm.71990
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A Stearyl‐Peptide Based Versatile Strategy to Design Enzyme‐Responsive Liposomes for Targeted Drug Delivery

Dante Disharoon, Bipin Chakravarthy Paruchuri, Keren Hu, Anirban Sen Gupta et al.
Advanced Healthcare Materials
Nanoparticle-Based Drug Delivery
article

A Stearyl‐Peptide Based Versatile Strategy to Design Enzyme‐Responsive Liposomes for Targeted Drug Delivery

Dante Disharoon, Bipin Chakravarthy Paruchuri, Keren Hu, Anirban Sen Gupta, Shruti P. Raghunathan, Elizabeth Wakelin, Sonali S. Rohiwal, Ujjal Didar Singh Sekhon, Norman F. Luc, Hanyang Wang, Rohini Sekar, Jenny Lian, Rahul Darbhakul
article en

Abstract

Liposomes are a prominent class of drug delivery nanoparticles. For currently approved liposomal therapeutics, drug is released predominantly via diffusion which has spatio-temporal kinetic and bioavailability challenges, especially in a dynamic environment. Next-generation liposome designs focus on stimuli-triggered enhancement of drug release. One exciting approach here is liposomes that can be site-specifically destabilized by disease-associated enzymes. Feasibility of this has been demonstrated with certain phospholipases or metalloproteases, but a versatile strategy for designing liposomes triggerable by any disease-specific enzyme remains lacking. We report a unique liposome design using enzyme-cleavable stearyl-peptide conjugates. Stearylamine has been explored for cationic liposomes in gene delivery, but the cationic charge poses significant cytotoxicity. We demonstrate that conjugating enzyme-cleavable peptides to stearylamine and assembly of stearyl-peptide conjugates within liposomes mitigates the cationic charge and significantly enhances biosafety. Surface-decorating such liposomes with target-specific ligands enables their active target-anchorage under flow. Exposure of target-anchored liposomes to disease-relevant enzymes renders stearyl-peptide cleavage and liposome destablization, enhancing drug release. We demonstrate the design versatility utilizing microfluidic models of three different vascular pathologies (hyperfibrinolysis, thrombosis and thromboinflammation) and delivering three corresponding drugs (tranexamic acid, tissue plasminogen activator and deoxyribonulease) triggered by three different enzymes (plasmin, thrombin and neutrophil elastase), respectively.

Advanced Healthcare Materials
Case Western Reserve University (US)
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon